These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 9752713)

  • 1. "Absolute" sterility and "absolute" freedom from particle contamination.
    Knapp JZ
    PDA J Pharm Sci Technol; 1998; 52(4):173-81. PubMed ID: 9752713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The scientific basis for visible particle inspection.
    Knapp JZ
    PDA J Pharm Sci Technol; 1999; 53(6):291-302. PubMed ID: 10754727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origin, result and measurement of USP "essentially free" inspection for visible contaminating particles.
    Knapp JZ
    PDA J Pharm Sci Technol; 2000; 54(3):218-32. PubMed ID: 10927913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Industrial manufacture of parenteral products in The Netherlands. A survey of eight years of media fills and sterility testing.
    Van Doorne H; Van Kampen BJ; Van der Lee RW; Rummenie L; Van der Veen AJ; De Vries WJ
    PDA J Pharm Sci Technol; 1998; 52(4):159-64. PubMed ID: 9752710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma sterilization of pharmaceuticals--a review of the irradiation of excipients, active pharmaceutical ingredients, and final drug product formulations.
    Hasanain F; Guenther K; Mullett WM; Craven E
    PDA J Pharm Sci Technol; 2014; 68(2):113-37. PubMed ID: 24668600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The limits of sterility assurance.
    von Woedtke T; Kramer A
    GMS Krankenhhyg Interdiszip; 2008 Sep; 3(3):Doc19. PubMed ID: 20204091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations.
    Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M
    PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sterility testing of antimicrobial-containing injectable solutions prepared in the pharmacy.
    Akers MJ; Wright GE; Carlson KA
    Am J Hosp Pharm; 1991 Nov; 48(11):2414-8. PubMed ID: 1746574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk analysis of sterile production plants: a new and simple, workable approach.
    Gapp G; Holzknecht P
    PDA J Pharm Sci Technol; 2011; 65(3):217-26. PubMed ID: 22293233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Problems in microbial safety of advanced therapy medicinal products. Squaring the circle].
    Montag-Lessing T; Störmer M; Schurig U; Brachert J; Bubenzer M; Sicker U; Beshir R; Spreitzer I; Löschner B; Bache C; Becker B; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):45-51. PubMed ID: 20012926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations for design and use of container challenge sets for qualification and validation of visible particulate inspection.
    Melchore JA; Berdovich D
    PDA J Pharm Sci Technol; 2012; 66(3):273-84. PubMed ID: 22634593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sterility Testing of Injectable Products: Evaluation of the Growth-based BacT/ALERT® 3D™ Dual T Culture System.
    Kaiser SJ; Mutters NT; Backhaus J; Frank U; Günther F
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):568-576. PubMed ID: 27325593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach.
    Langille SE
    PDA J Pharm Sci Technol; 2020; 74(3):359-366. PubMed ID: 31732691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and use of a novel peracetic acid sterilizer for absolute barrier sterility testing chambers.
    Davenport SM
    J Parenter Sci Technol; 1989; 43(4):158-66. PubMed ID: 2769522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Risk- and Science-Based Approach to the Acceptance Sampling Plan Inspection of Protein Parenteral Products.
    Spasoff A; Bennis A; Atkinson S; Elliott C; Freund E; Narhi L
    J Pharm Sci; 2018 Sep; 107(9):2306-2309. PubMed ID: 29859961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alternative sterility assessment for parenteral drug products using isothermal microcalorimetry.
    Brueckner D; Krähenbühl S; Zuber U; Bonkat G; Braissant O
    J Appl Microbiol; 2017 Sep; 123(3):773-779. PubMed ID: 28776899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the BacT/ALERTR 3D system for sterility testing of injectable products.
    Bugno A; Lira RS; Oliveira WA; Almodovar AA; Saes DP; Pinto Tde J
    Braz J Microbiol; 2015; 46(3):743-7. PubMed ID: 26413055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sterility test systems for product recovery.
    Gee LW; Harvey JM; Olson WP; Lee ML
    J Pharm Sci; 1985 Jan; 74(1):29-32. PubMed ID: 3981412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Justification for the use of aseptic filling for sterile injectable products.
    Cundell AM
    PDA J Pharm Sci Technol; 2014; 68(4):323-32. PubMed ID: 25035255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.